Showing results (571-580 of 594) with videos related to
Sort By:
Pageof 60
Vaccine|April 27, 2022
Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trialsFeng-Cai Zhu, Hao Zeng, Jing-Xin Li, et al.Signal Transduction and Targeted Therapy|July 16, 2021
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFan-Yue Meng, Fan Gao, Si-Yue Jia, et al.Expert Review of Vaccines|March 26, 2024
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studiesAbundio Balgos, Suad Hannawi, Wen-Li Chen, et al.Frontiers in Oncology|August 15, 2022
Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOXXi Zhang, Qing-Hong Chen, Ying Yang, et al.Lancet (London, England)|July 5, 2015
Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trialMing Zeng, Xu-Hu Mao, Jing-Xin Li, et al.Journal of Ethnopharmacology|April 8, 2026
Erchen Decoction Promotes Inguinal White Adipose Tissue Browning via the M2 Macrophage-Sympathetic Axis to Ameliorate Obesity in MiceJia-Wei Chen, Mao-Hui Liu, Zhi-Da Yang, et al.Lancet (London, England)|May 26, 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialFeng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, et al.Eclinicalmedicine|January 3, 2024
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)Yi Fang, Jing-Xin Li, Davone Duangdany, et al.The Lancet. Respiratory Medicine|March 10, 2023
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Hui Zheng, Bu-Sen Wang, et al.Ebiomedicine|April 26, 2023
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trialYu-Zhou Gui, Xue-Ning Li, Jing-Xin Li, et al.Pageof 60